J
Jean Bourhis
Researcher at University of Lausanne
Publications - 390
Citations - 29983
Jean Bourhis is an academic researcher from University of Lausanne. The author has contributed to research in topics: Radiation therapy & Medicine. The author has an hindex of 70, co-authored 335 publications receiving 25255 citations. Previous affiliations of Jean Bourhis include Institut de radioprotection et de sûreté nucléaire & University of Paris.
Papers
More filters
Journal ArticleDOI
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh,François Ghiringhelli,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Michel Obeid,Michel Obeid,Michel Obeid,Carla Ortiz,Carla Ortiz,Carla Ortiz,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,M. Chiara Maiuri,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Patrick Saulnier,Huan Yang,Sebastian Amigorena,Bernard Ryffel,Franck J. Barrat,Paul Saftig,Francis Lévi,Francis Lévi,Rosette Lidereau,Catherine Noguès,Jean-Paul Mira,Agnès Chompret,Virginie Joulin,Françoise Clavel-Chapelon,Jean Bourhis,Fabrice Andre,Suzette Delaloge,T. Tursz,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +42 more
TL;DR: A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.
Journal ArticleDOI
Postoperative Irradiation With or Without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
Jacques Bernier,Christian Domenge,Mahmut Ozsahin,Katarzyna Matuszewska,Jean-Louis Lefebvre,Richard H. Greiner,Jordi Giralt,Philippe Maingon,Frederic Rolland,M. Bolla,Francesco Cognetti,Jean Bourhis,Anne Kirkpatrick,Martine Van Glabbeke +13 more
TL;DR: Postoperative concurrent administration of high-dose cisplatin with radiotherapy is more efficacious than radiotherapy alone in patients with locally advanced head and neck cancer and does not cause an undue number of late complications.
Journal ArticleDOI
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
TL;DR: In this paper, the authors conducted an individual patient data (IPD) meta-analysis, which showed that chemotherapy improved survival in patients curatively treated for non-metastatic head and neck squamous cell carcinoma (HNSCC), with a higher benefit with concomitant chemotherapy.
Journal ArticleDOI
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
Jacques Bernier,Jay S. Cooper,Thomas F. Pajak,M. van Glabbeke,Jean Bourhis,Arlene A. Forastiere,Esat Mahmut Ozsahin,John R. Jacobs,Jacek Jassem,K. Kian Ang,J.L. Lefebvre +10 more
TL;DR: Level I evidence was established for the postoperative adjuvant treatment of patients with selected high‐risk locally advanced head and neck cancers, with the publication of the results of two trials conducted in Europe and the United States.
Journal ArticleDOI
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
Jean Bourhis,Jens Overgaard,Hélène Audry,Kian K. Ang,M.I. Saunders,Jacques Bernier,Jean-Claude Horiot,Aurélie Le Maître,Thomas F. Pajak,Michael Poulsen,Brian O'Sullivan,W. Dobrowsky,Andrzej Hliniak,Krzysztof Składowski,John Hay,Luiz H. J. Pinto,Carlo Fallai,Karen K. Fu,Richard Sylvester,Jean-Pierre Pignon +19 more
TL;DR: Comparison of the different types of altered radiotherapy suggests that hyperfractionation has the greatest benefit, whereas the benefit on nodal control was less pronounced.